Solutions that cure
People who care
Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines.
The company’s experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics' scientists to conduct research at state-of-the-art facilities.
About us
BREAKTHROUGH
EXG-5003
RNA Vaccine for COVID-19
EXG-5003 is an intradermally-injected RNA vaccine expressing the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. EXG-5003 uses Elixirgen Therapeutics’ proprietary RNA vaccine platform.
Elixirgen Therapeutics concluded its pre-IND meeting with the FDA on May 18, 2020, and has announced the start of dosing in a Phase 1/2 clinical trial in Japan on May 25, 2021.
Our Covid-19 VaccineEXG34217
Our Cell Therapy
EXG34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure that uses Elixirgen Therapeutics’ proprietary ZSCAN4 technology to extend the telomeres of the patients.
